A Misalignment of AI and Cancer Biology (twitter.com)

Recent advancements in AI, particularly in large language models (LLMs), have led to groundbreaking successes in curing previously untreatable cancers. However, these developments have sparked concerns within the cancer biology community about a significant misalignment of goals between AI companies and scientists. While AI may quickly produce “cancer-free” results, the process bypasses the critical scientific rigor of understanding cancer biology—an essential journey involving hypothesis generation, experimentation, peer review, and the development of new concepts. This shift threatens to diminish the nuanced insights that have historically guided cancer research and therapy development. The crux of the issue lies in the potential rush to market AI-conceived treatments, which may result in a lack of proper documentation and attribution, undermining the intellectual work of cancer biologists. As AI continues to generate quick results, questions arise about how to maintain the integrity of human intellectual endeavor and ensure that the ultimate goal remains understanding rather than mere outputs. The future of cancer biology hinges on how well the field adapts to these emerging AI capabilities, emphasizing the importance of human oversight in preserving the core values of research and collaboration amidst technological advancements.